Instruments

Name Stock exchange Average volume Price Type
DAPHNE INTERNATIONAL HOLDINGS LIMITED 210

Hong Kong S.E. +4 Other

3,957,000 0.168 HKD Stock Daphne International Holdings Limited Stock
DAPHNE INTERNATIONAL HOLDINGS LIMITED PSX

Deutsche Boerse AG

- 0.016 EUR Stock Daphne International Holdings Limited
DAPHNE INTERNATIONAL HOLDINGS LIMITED PSX

Börse Stuttgart

- 0.016 EUR Stock Daphne International Holdings Limited
DAPHNE INTERNATIONAL HOLDINGS LIMITED PSX

BOERSE MUENCHEN

- 0.023 EUR Stock Daphne International Holdings Limited
DAPHNE INTERNATIONAL HOLDINGS LIMITED DPNEF

OTC Markets

0 0.0173 USD Stock Daphne International Holdings Limited
DAPHNE INTERNATIONAL HOLDINGS LIMITED DPNEY

OTC Markets

0 0.4502 USD Stock Daphne International Holdings Limited Stock

News (147)

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments BU
PureTech Health : Notice of Meeting for 2024 AGM PU
PureTech Announces Annual Results for Year Ended December 31, 2023 BU
Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines AQ
PureTech Health CEO Zohar moves to head-up portfolio firm Seaport AN
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions BU
PureTech Health plc Announces Chief Executive Officer Changes CI
PureTech Health plc Announces Management Changes CI
Seaport Therapeutics announced that it has received $100 million in funding from Arch Venture Partners, L.P., Sofinnova Investment, Inc., Third Rock Ventures, LLC, PureTech Health plc CI
European markets flat ahead of Fed and BoE AN
PureTech shares jump on USD100 million tender offer proposal AN
PureTech Proposes $100 Million Capital Return BU
PureTech Health : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K PU
PureTech to Present at Two Upcoming Investor Conferences BU
Transcript : PureTech Health plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference BU
PureTech makes strong progress, expects "multiple catalysts" next year AN
PureTech Year End Update and Outlook for 2024 BU
PureTech Health : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K PU
PureTech s LYT-300 Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers AQ
PureTech Health celebrates positive results in Phase 2 anxiety trial AN
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers BU
PureTech to Present at Two Upcoming Investor Conferences BU
Arix Bioscience boosts net value, CEO jumping ship for PureTech Health AN
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer BU
PureTech Health plc - Half-Year Report AQ
Transcript : PureTech Health plc, H1 2023 Earnings Call, Aug 29, 2023
PureTech narrows interim loss despite "stormy market challenges" AN
FTSE 100 catches up with bank holiday rally AN
Bunzl profit up; Rio Tinto sells copper project stake AN
PureTech Health plc – Half-Year Report BU
Results of PureTech's Annual General Meeting BU
PureTech Announces Annual Results for Year Ended December 31, 2022 AQ
Transcript : PureTech Health plc, 2022 Earnings Call, Apr 28, 2023
PureTech Health yearly loss widens but remains optimistic AN
PureTech Health : Notice of Meeting for 2023 AGM PU
PureTech Health : Proxy Form for 2023 AGM PU
PureTech Announces Annual Results for Year Ended December 31, 2022 BU
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million GL
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million AQ
PureTech Health says Royalty Pharma acquires Karuna Royalties AN
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million BU
PureTech to Present at the SVB Securities Global Biopharma Conference BU
Transcript : PureTech Health plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 02:15 PM
PureTech Provides End of Year Report on Key Progress BU
1234NextSee all

Companies (2)

DAPHNE INTERNATIONAL HOLDINGS LIMITED 43 M $
Logo Daphne International Holdings Limited

Daphne International Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture, distribution and retailing of footwear products and accessories. The Company operates through three segments. The Core Brands seg ...

UNITED BANCORPORATION OF ALABAMA, INC. 165 M $
Logo United Bancorporation of Alabama, Inc.

United Bancorporation of Alabama, Inc. is a financial holding company that primarily serves Southwest Alabama as well as Northwest Florida. The Company is a Community Development Financial Institution (CDFI) that operates three subsidiaries: United Bank, ...


Insiders

Picture Daphne Zohar
Daphne Zohar

Daphne Zohar is the founder of Tal Medical, Inc. (founded in 2010), Puretech Health LLC (founded in 2005), Follica, Inc. (founded in 2006), Libra Biosciences, Inc. (founded in 2009), Mandara Sciences LLC (founded in 2010), and PureTech Health Plc (founded in 2015).
She held various titles at these companies, including Director, Chief Executive Officer & Director, President, Secretary, Treasurer & Director.
Ms. Zohar is also the founder of Karuna Therapeutics, Inc., Seaport Therapeutics, Inc., and other companies.
Her current job(s) include President, Secretary, Treasurer & Director at Appeering, Inc., Director at Knode, Inc., Director at Commense, Inc., and Board Member at Biotechnology Innovation Organization.
Her former job(s) include Interim Chief Executive Officer at Satori Pharmaceuticals, Inc., Director at Solace Pharmaceuticals, Inc., Director at Whitehead Institute for Biomedical Research, Director at Enlight Biosciences LLC, Director at ENDRA Life Sciences, Inc., Director at Vedanta Biosciences, Inc., Director at The Sync Project, Inc., and Director at resTORbio, Inc. (2017-2018).
Ms. Zohar's education history includes an undergraduate degree from Northeastern University.


Picture Shlomo Zohar
Shlomo Zohar

Shlomo Zohar is currently the Chairman at Extra Retail Group Ltd., Bait Ve Gag Real Estate Development Ltd., and an Independent Director at Isras Investment Co. Ltd., Partner Communications Co. Ltd., and Ham-Let (Israel-Canada) Ltd.
He is also a Director at Sonol Israel Ltd., Leumi Partners Ltd., Bee Group Retail Ltd., Mega Retail Ltd., Tempo Beverages Ltd., Dan Public Transportation Co. Ltd., Delek US Holdings, Inc., Noble Assets (BVI) Ltd., Zohar S Consulting & Management Ltd., RST Cleantech Solutions Ltd., ISPAC 1 Ltd., and Principal at Noy Infrastructure & Energy Investment Fund.
Formerly, Mr. Zohar served as the Chief Executive Officer at A.D.O.
Group Ltd.
from 2011 to 2018.
He was the Chairman of Israel Discount Bank Ltd., Mercantile Discount Bank Ltd., Israel Discount Bank of New York, Israel Discount Capital Markets & Investments Ltd., and Israel Credit Cards Ltd.
from 2006 to 2009.
He also held the position of Vice Chairman at Israel Discount Bank Ltd.
during the same period.
Additionally, he was the Chairman of B Communications Ltd.
and Vice Chairman of ADLER Group SA. He briefly served as the Executive Vice Chairman of ADLER Group SA in 2018.
He has also been a Director at Alon Blue Square Israel Ltd., Delek US Energy, Inc., and Discount Bancorp, Inc. Furthermore, he was a Partner at Zohar, Zohar & Co. Certified Public Accountants Co. from 1980 to 2005.
Mr. Zohar obtained an MBA from McGill University in 1980 and completed his undergraduate studies at Bar-Ilan University.




Picture Zohar Alon
Zohar Alon

Zohar Alon was the founder of Check Point Public Cloud Security Ltd.
(founded in 2011) and Dome9 Security, Inc. (founded in 2010), where he held the titles of Chief Executive Officer and Director respectively.
Currently, he is the Chairman of Tamnoon, Inc. and an Investor at D.
E.
Shaw Laminar Portfolios LLC, where he holds the title of Investor.
He is also an Advisory Board Member at Monogoto Ltd.
Mr. Alon's former job was as a Venture Partner at Evolution Venture Capital from 2010 to 2016.
He received his undergraduate degree from Tel-Aviv University.




Picture Zohar Yardeni
Zohar Yardeni

Zohar Yardeni is the founder of Radius IM LLC, which was founded in 2005.
He was the Co-Chief Executive Officer from 2010 to 2011.
Mr. Yardeni is also the founder of CallStreet LLC.
Currently, he is a Director at Axiom Global, Inc. Mr. Yardeni's former positions include being the Chief Executive Officer at Main Street Connect LLC, a Statistical Analyst at Lazard Frères & Co. LLC, Vice President-Products at ZocDoc, Inc., and Global Head-Product Management at Thomson Reuters Corp.
He was also the Executive Vice President-Product at XO Group, Inc. from 2018 to 2019.
Mr. Yardeni received his undergraduate degree from Cornell University in 1995 and his MBA from Columbia Business School in 2001.


Picture Nadav Zohar
Nadav Zohar

Nadav Zohar is the founder of Impact Equity Corp.
He currently holds the position of Chairman at LRC Group since 2006, Chairman at Xcap Ecosystem Ltd., and Independent Director at Allot Ltd.
since 2017.
Previously, he served as Non-Executive Chairman at Soluto Ltd.
from 2008 to 2013, Chairman at Stoa USA, Inc., Independent Director at Finnovate Acquisition Corp., and Executive Director-Financial Sponsors Group at Morgan Stanley from 2001 to 2006.
He also held the role of Independent Non-Executive Director at Automax Motors Ltd.
from 2014 to 2017, Associate at Jones Day Gouldens from 1991 to 1996, Vice President-Mergers & Acquisitions at Lehman Brothers Ltd.
from 1997 to 2001, Head-Corporate Development at GT Gettaxi Services Israel Ltd.
from 2015 to 2018, Vice President at Lehman Brothers International, Inc. from 1996 to 1999, Head-Business Development at Gett, Inc. from 2014 to 2018, and Chief Operating Officer at Delek Global Real Estate Plc from 2006 to 2009.
He obtained a graduate degree from The University of Reading and London Business School.


No results for this search